Compare Carvana Co (CVNA) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carvana Co vs Sana Biotechnology Inc — how do they compare? Carvana Co trades at $63.8 (market cap $69.55B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: Carvana Co is far larger — about 83.1× Sana Biotechnology Inc's market cap, and Carvana Co is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Carvana Co for 28 Days and Sana Biotechnology Inc for 23 Days on average.
| CVNA | SANA | |
|---|---|---|
Market Cap | $69.55B | $836.71M |
Volume | 7,671,750 | 4,507,444 |
Sector | Consumer Cyclical | Health |
52-Week High | $95.69 | $5.92 |
52-Week Low | $56.27 | $2.68 |
Typical Hold Time | 28 Days | 23 Days |
Enterprise Value | $72.04B | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carvana (CVNA) trades at $63.73, up 1.55% today, showing strong fundamental momentum with revenue surging to $20.32B in 2025 and net income reaching $1.41B. The stock has consistently beaten earnings expectations in recent quarters, though technical indicators signal bearish pressure with key resistance at $64-65. Recent news highlights Carvana as the 'best story' in autos with September sales beating estimates by 40%.
Carvana presents a compelling growth story with expanding profitability and aggressive capacity expansion, though high debt levels and volatile technical signals warrant caution. Analyst consensus targets $84.07 (32% upside) with 46% buy ratings, but investors face execution risks from inventory constraints and competitive pressures in the used car market.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Carvana Co
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
